These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 15824414

  • 1. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC.
    J Clin Oncol; 2005 May 20; 23(15):3404-11. PubMed ID: 15824414
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE.
    J Clin Oncol; 2004 Mar 15; 22(6):1110-7. PubMed ID: 15020613
    [Abstract] [Full Text] [Related]

  • 3. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
    Dai G, Chan KK, Liu S, Hoyt D, Whitman S, Klisovic M, Shen T, Caligiuri MA, Byrd J, Grever M, Marcucci G.
    Clin Cancer Res; 2005 Apr 15; 11(8):2998-3008. PubMed ID: 15837754
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI.
    Clin Cancer Res; 2002 Mar 15; 8(3):679-83. PubMed ID: 11895895
    [Abstract] [Full Text] [Related]

  • 5. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR, Hogarty MD, Blaney SM, Zwiebel JA, Sauk-Schubert C, Chandula R, Krailo MD, Adamson PC, Children's Oncology Group Study.
    J Clin Oncol; 2007 Apr 20; 25(12):1512-8. PubMed ID: 17442993
    [Abstract] [Full Text] [Related]

  • 6. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
    Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG.
    J Clin Oncol; 2005 Jun 20; 23(18):4089-99. PubMed ID: 15867202
    [Abstract] [Full Text] [Related]

  • 8. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 9. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug 15; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 10. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
    Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA.
    Blood; 2003 Jan 15; 101(2):425-32. PubMed ID: 12393493
    [Abstract] [Full Text] [Related]

  • 11. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 12. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.
    Clin Cancer Res; 2004 Aug 01; 10(15):5048-57. PubMed ID: 15297406
    [Abstract] [Full Text] [Related]

  • 13. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG, Oblimersen Melanoma Study Group.
    J Clin Oncol; 2006 Oct 10; 24(29):4738-45. PubMed ID: 16966688
    [Abstract] [Full Text] [Related]

  • 14. Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial.
    Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, Lübbert M, Noens L, Schlimok G, Arnold R, Kirchner H, Ganser A.
    Ann Hematol; 2004 Jun 10; 83(6):336-44. PubMed ID: 15034758
    [Abstract] [Full Text] [Related]

  • 15. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
    O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR.
    J Clin Oncol; 2005 Oct 20; 23(30):7697-702. PubMed ID: 16186597
    [Abstract] [Full Text] [Related]

  • 16. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C, Hassan HT.
    Leuk Res; 2006 Mar 20; 30(3):296-302. PubMed ID: 16112192
    [Abstract] [Full Text] [Related]

  • 17. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K.
    Clin Cancer Res; 2003 Sep 15; 9(11):4267-73. PubMed ID: 14519654
    [Abstract] [Full Text] [Related]

  • 18. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X, Elhamri M, Chelghoum Y, Reman O, Arnaud P, Raffoux E, Le QH, Tavernier E, Dombret H, Michallet M.
    Ann Hematol; 2005 Jun 15; 84(6):376-82. PubMed ID: 15782343
    [Abstract] [Full Text] [Related]

  • 19. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F.
    Ann Hematol; 2009 Feb 15; 88(2):151-8. PubMed ID: 18709502
    [Abstract] [Full Text] [Related]

  • 20. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E.
    Cancer; 2004 Feb 01; 100(3):581-9. PubMed ID: 14745876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.